BBO 8520
Alternative Names: BBO-8520Latest Information Update: 14 Jan 2025
Price :
$50 *
At a glance
- Originator BridgeBio Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 09 Jan 2025 BBO 8520 receives Fast Track designation for Non-small cell lung cancer [PO] (Late-stage disease, Metastatic disease, Monotherapy) in USA
- 09 Dec 2024 Pharmacodynamics data from a preclinical study in Cancer released by BridgeBio Oncology therapeutics
- 19 Apr 2024 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in Australia (PO) (NCT06343402)